Date:2/9/2011

management of oral mucositis when undergoing radiation and chemotherapy for many different cancers, including head and neck, lung, colon and breast cancer," said Frank Jacobucci, VP of Sales and Marketing, Access Pharmaceuticals, Inc.  He continued, "We are pleased with the ongoing clinical success doctors and nurse practitioners are experiencing when prescribing MuGard to protect their patients from oral mucositis."

About MuGard:MuGard is a novel, ready-to-use, easy-to-swallow, mucoadhesive oral wound liquid that provides a protective polymer coating over the mucosa.  MuGard received 510(k) marketing allowance in the US with a broad indication for treating lesions of the mouth including the management of oral mucositis. In Europe, MuGard is a class IIa medical device which has been granted CE mark certification with the following indication: prevention and management of the lesions and symptoms of oral mucositis Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.

About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of pat
'/>"/>

SOURCE Access Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Ness County Hospital Selects ChartAccess® Comprehensive EHR from Prognosis Health Information Systems
2. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
3. Cancer Patients in Bangladesh Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems
4. Medicare Patients Report Problems With Access to Medically Required Equipment and Services Under Controversial Competitive Bidding System
5. Access MediQuip Names Prakash Patel Chief Executive Officer
6. Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment
7. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
8. EDC Functionality, Ease of Data Entry, and Access to Data All Factors in University of Virginia Cancer Centers Selection of the OnCore Clinical Research Management System
9. AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device
10. Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants
11. Critical Care Nurses Do Not Have Access to Tools They Need to Treat Sepsis